Peptide directoryHeart, vessels & kidneys

Angiotensin III

Angiotensin II minus one, and the brain’s own pressor.

Where it comes from

Made in
Made from angiotensin II by aminopeptidase A, in blood, kidney and brain
Sent out by
Follows angiotensin II
Acts on
  • Adrenal cortex
  • Brain (vasopressin release, thirst)
  • Kidney

What it does

  • Releases aldosterone as strongly as angiotensin II, so an aldosterone result reflects both 3
  • In the brain it, and not angiotensin II, raises blood pressure and releases vasopressin 1
  • Weaker as a direct constrictor and shorter-lived, because the next aminopeptidase is waiting 1

In medicine

  • No medicine and no test of its own. Assays for angiotensin II generally cannot exclude it, since one residue separates them
  • It is the reason the brain arm of this system is treated as a separate problem: blocking angiotensin II in the blood does not reach what angiotensin III does inside the brain 1

Beyond the body’s own use

  • Firibastat, a brain aminopeptidase A inhibitor designed to stop its formation, failed to lower blood pressure meaningfully in difficult-to-treat and resistant hypertension in the FRESH trial, and its development stopped 2
  • That failure is the honest summary of the field: a convincing animal story about brain angiotensin III did not survive a randomised trial in people 12
  • Nothing is in trials now and nothing is claimed for the peptide itself

Sources

  1. Réaux et al., PC18, an aminopeptidase N inhibitor, induces vasopressin release by extending the half-life of brain angiotensin III, Neuroendocrinology 1999
  2. Zoccali et al., New trials in resistant hypertension: mixed blessing stories, Clinical Kidney Journal 2024
  3. Paul et al., Physiology of local renin-angiotensin systems, Physiological Reviews 2006

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.